Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Features

Reimbursement Issues Seem to Be Holding Renal Denervation Back

Todd Neale

December 19, 2024

Presentation TCT 2024

TCT 421: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in U.S. Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW-VII Trial

Presenter: David Kandzari

October 28, 2024

Presentation TCT 2024

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

Presenter: David Kandzari

October 28, 2024

News Daily News

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

Todd Neale

August 23, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation THT 2024

Initial Results from the First-in-Human Study of the Supira System

Presenter: David E. Kandzari

March 06, 2024

News Daily News

‘Green Cardiovascular Care’ Needed to Protect Environment, Bolster Health

Caitlin E. Cox

January 11, 2024

News Daily News

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Michael O'Riordan

January 09, 2024

Advertisement

Reimbursement Issues Seem to Be Holding Renal Denervation Back

TCT 421: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in U.S. Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW-VII Trial

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Initial Results from the First-in-Human Study of the Supira System

‘Green Cardiovascular Care’ Needed to Protect Environment, Bolster Health

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content